Teva Pharmaceutical Industries Ltd (Teva) (TASE:TEVA) (HYSE:TEVA) announced on Monday the launch of a generic version of VESIcare 1 (solifenacin succinate) tablets, 5 mg and 10 mg, in the US.
Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. Overactive bladder (OAB) is most often characterised by a strong sudden urge to urinate that is difficult to control.
Reportedly, VESIcare tablets had annual sales of over USD955m in the US, according to IQVIA data as of February 2019.
According to Teva, with nearly 500 generic medicines available, it has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in eight generic prescriptions dispensed in the US is filled with a Teva generic product.
Teva Pharmaceutical Industries is a leader in generic and specialty medicines with a portfolio consisting of over 35,000 products in nearly every therapeutic area.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US